Paper Details

  1. Home
  2. Paper Details

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

Author: ChenC W, ChenS J, ChengJ, DongJ, GaoZ L, HouJ L, JiY, JiaJ D, LiJ, MaoQ, MaoY M, NingQ, NiuJ Q, PanC, RenH, ShengJ F, TanD M, TangH, WangH, WuS M, XieQ, XuM, ZhangJ M, ZhangX X, ZhaoW

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tenofovir disoproxil fumarate (TDF) is an effective treatment for chronic hepatitis B (CHB). This study compared the efficacy and safety of TDF and adefovir dipivoxil (ADV) in Chinese patients with CHB. TDF was found to be superior to ADV in terms of viral suppression and did not lead to the development of resistance.
Paper Details　
Original Abstract of the Article :
Tenofovir disoproxil fumarate (TDF) has demonstrated long-term efficacy and a high barrier to resistance in multiple chronic hepatitis B (CHB) populations outside of China. This study aimed to evaluate the efficacy and safety of TDF compared with adefovir dipivoxil (ADV) in Chinese patients with CHB...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.12313

データ提供：米国国立医学図書館（NLM）

Tenofovir vs Adefovir: A Comparative Study in Chronic Hepatitis B

Chronic hepatitis B (CHB) is a serious liver infection, and finding effective treatments is crucial for preventing long-term complications. This randomized controlled trial compares the efficacy and safety of tenofovir disoproxil fumarate (TDF) with adefovir dipivoxil (ADV) in Chinese patients with CHB, providing valuable insights into the optimal treatment approach.

Tenofovir Emerges as a Superior Treatment

The study found that TDF demonstrated superior viral suppression compared to ADV in both HBeAg-positive and HBeAg-negative patients, with no evidence of resistance to TDF. The authors conclude that TDF is a safe and effective treatment option for Chinese patients with CHB.

Navigating the Landscape of Hepatitis B Treatment

This research is like a camel finding a reliable water source in the desert. The authors provide valuable information for clinicians treating CHB in China, demonstrating the superior efficacy and safety of TDF compared to ADV. Their findings contribute to the growing body of evidence supporting the use of TDF as a preferred treatment for CHB.

Dr.Camel's Conclusion

This study provides strong evidence for the superiority of tenofovir disoproxil fumarate (TDF) over adefovir dipivoxil (ADV) in treating chronic hepatitis B (CHB) in Chinese patients. The authors demonstrate TDF's superior viral suppression, safety, and lack of resistance development, making it a valuable treatment option for this challenging condition. This research provides clinicians with valuable information to guide their treatment decisions and improve outcomes for patients with CHB.

Date :
  1. Date Completed 2015-10-09
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

25243325

DOI: Digital Object Identifier

10.1111/jvh.12313

Related Literature

Article Analysis
・Side Effects of adefovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.